DE69733957D1 - Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta - Google Patents

Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta

Info

Publication number
DE69733957D1
DE69733957D1 DE69733957T DE69733957T DE69733957D1 DE 69733957 D1 DE69733957 D1 DE 69733957D1 DE 69733957 T DE69733957 T DE 69733957T DE 69733957 T DE69733957 T DE 69733957T DE 69733957 D1 DE69733957 D1 DE 69733957D1
Authority
DE
Germany
Prior art keywords
beta
procedure
detecting
specific protein
brain specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733957T
Other languages
English (en)
Other versions
DE69733957T2 (de
Inventor
Jan Brundell
Lena Nyberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diasorin AB
Original Assignee
Diasorin AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diasorin AB filed Critical Diasorin AB
Publication of DE69733957D1 publication Critical patent/DE69733957D1/de
Application granted granted Critical
Publication of DE69733957T2 publication Critical patent/DE69733957T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69733957T 1996-07-05 1997-06-27 Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta Expired - Lifetime DE69733957T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602677 1996-07-05
SE9602677A SE9602677D0 (sv) 1996-07-05 1996-07-05 Methods for determining brain antigens
PCT/SE1997/001164 WO1998001471A1 (en) 1996-07-05 1997-06-27 Methods for determining the presence of brain protein s-100

Publications (2)

Publication Number Publication Date
DE69733957D1 true DE69733957D1 (de) 2005-09-15
DE69733957T2 DE69733957T2 (de) 2006-04-13

Family

ID=20403304

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733957T Expired - Lifetime DE69733957T2 (de) 1996-07-05 1997-06-27 Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta

Country Status (13)

Country Link
EP (1) EP0931094B1 (de)
JP (1) JP2000515854A (de)
AT (1) ATE301671T1 (de)
AU (1) AU715797B2 (de)
BR (1) BR9710175A (de)
CA (1) CA2259413A1 (de)
DE (1) DE69733957T2 (de)
ES (1) ES2247633T3 (de)
IL (1) IL127278A0 (de)
NO (1) NO986218D0 (de)
NZ (1) NZ333408A (de)
SE (1) SE9602677D0 (de)
WO (1) WO1998001471A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107994B1 (de) * 1998-08-28 2006-04-26 Canag Diagnostics AB Monoklonale antikörper gegen s100
CA2349593A1 (en) * 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2001023894A1 (de) * 1999-09-28 2001-04-05 Evotec Oai Ag Quantitative analyse und typisierung subzellulärer partikel
AU2001265714A1 (en) * 2000-06-14 2001-12-24 Universite Libre De Bruxelles Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases
ES2394972B2 (es) * 2011-06-17 2013-07-19 Universidade De Santiago De Compostela Péptido antigénico aislado derivado de la proteína s100-beta, procedimiento de identificación y su uso en la prevención, tratamiento, diagnóstico y/o seguimiento de la diabetes tipo i.
ES2394331B2 (es) * 2011-06-17 2013-07-15 Universidade De Santiago De Compostela Uso de un péptido antigénico aislado derivado de la proteína s100-beta no unido a una molécula mhc de clase ii en la prevención, tratamiento, diagnóstico y/o seguimiento de la diabetes tipo i
CN102331502B (zh) * 2011-08-31 2013-12-04 内蒙古科慧生物科技有限责任公司 人s100蛋白(s-100)定量测定试剂盒
WO2014194329A1 (en) * 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
CN111487409A (zh) * 2019-01-28 2020-08-04 艾维可生物科技有限公司 一种s100b蛋白的化学发光法检测试剂盒及其使用方法

Also Published As

Publication number Publication date
AU3563397A (en) 1998-02-02
NZ333408A (en) 1999-05-28
BR9710175A (pt) 2000-01-11
NO986218L (no) 1998-12-30
WO1998001471A1 (en) 1998-01-15
SE9602677D0 (sv) 1996-07-05
NO986218D0 (no) 1998-12-30
IL127278A0 (en) 1999-09-22
CA2259413A1 (en) 1998-01-15
JP2000515854A (ja) 2000-11-28
ES2247633T3 (es) 2006-03-01
DE69733957T2 (de) 2006-04-13
AU715797B2 (en) 2000-02-10
EP0931094A1 (de) 1999-07-28
ATE301671T1 (de) 2005-08-15
EP0931094B1 (de) 2005-08-10

Similar Documents

Publication Publication Date Title
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
ATE140963T1 (de) Verfahren zur herstellung von sekretierten rezeptoranalogen
DE3786200D1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
ATE209356T1 (de) Ein verfahren zur bestimmung von kollagenfragmenten in körperflüssigkeiten, ein testkit und mittel zur durchführung des verfahrens, und seine verwendung zur feststellung von mit dem kollagenmetabolismus assoziierten störungen
DE69733957D1 (de) Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta
ATE190728T1 (de) Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper
HUP0103650A2 (hu) Vírusburok-proteinek epitópjai és az ellenük termelt ellenanyagok alkalmazása HCV-vírusantigén gazdaszövetből történő kimutatására
KR970700772A (ko) T 세포 항원 수용체의 v 영역 단백질 및 그것의 제조 방법(t cell antigen receptor v region proteins and methods of preparation thereof)
ATE130102T1 (de) Verfahren zur identifizierung oder bestimmung von proteinen und verwendungen dazu.
KR950008537A (ko) 엡스타인 바 비루스(ebv)에 대한 항체의 검출용 진단제
EP0869177A3 (de) Menschliche Typ-A und Typ-B Blutplättchen abstammenden Wachstumfaktor Rezeptoren
ATE200709T1 (de) Htlv-i/htlv-ii assay und verfahren
BRPI0406265A (pt) Método para análise eletroforética capilar, métodos para pesquisa e tipagem de proteìnas monoclonais, processo para preparação de anticorpos modificados, anticorpos modificados, kit para detecção e tipagem de proteìnas monoclonais e uso de anticorpos
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
ATE306666T1 (de) Verfahren zur eiweissanalyse
DE69016858D1 (de) Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
SE9002212D0 (sv) Igg binding protein
FR2722508B1 (fr) Cassette d'expression d'une proteine p30 de toxoplasma gondii
ATE124706T1 (de) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben.
Lloyd et al. The antigenic constituents of cattle skin washings
EP0295719A3 (de) SM-D-Antigen, Klonierung von SM-D-Antigen und Nachweis von systemischen Lupus Erythematoden durch Benutzung von SM-D-Antigen
EP0307858A3 (en) The sm-b/b1 antigens, the cloning of the sm-b/b1 antigens and the detection of systemic lupus erythematosus by using the sm-b/b1 antigens or a mixture of the sm-b/b1 and sm/d antigens
ATE134218T1 (de) Methode zur reinigung rekombinanter t-pa von den ihren entsprechenden wirtszellproteinen
SE8803986D0 (sv) Method for sequencing peptides or proteins
DE3783840D1 (de) Verfahren zur bestimmung von plasma-protein und testsatz dafuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition